🔴 Arcturus Therapeutics is trading 6.5% down in pre-market with no company-specific cause identified

Arcturus Therapeutics is trading 6.5% lower at $10.35 in pre-market, as weaker risk sentiment and geopolitical tensions may be contributing; no company-specific cause was identified.

• U.S. futures and major indexes were lower in pre-market; biotech-sector strength is contrary context, and the decline does not appear sector-led.
• A company announcement on interim OTC deficiency results and its LUNAR 2.0 platform was published October 22, but dates the announcement September 23 and does not link it to the stock move.